Exchange: NASDAQ·Updated 10:28 AM EDT
ADPT logo

ADPTAdaptive Biotechnologies Corp

$23.55
$0.99
(4.39%)
Today
Reported EarningsJul 29
Mkt Cap$3.61B
Vol1.03M
News
all
press releases
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
More News
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?
Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.read more...
Benzinga
Are Medical Stocks Lagging DexCom (DXCM) This Year?
Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Zacks
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Key PointsApproximately 386,000 shares were liquidated for a total transaction value of $8.5 million on July 2, 2026...
Nasdaq News: Markets
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT...
Yahoo! Finance: News
Wednesday's ETF Movers: ARKG, SLVR
In trading on Wednesday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 7.9% on the day. Components of that ETF showing particular strength include shares of Absci, up about 38.3% and shares of Adaptive Biotechnologies, up about 13.7% on the day. And unde...
Nasdaq News: Markets
<
1
2
>

Advertisement|Remove ads.